Cyclooxygenase 2 inhibitors and lung carcinoma

Jean‐Philippe Spano; Kader Chouahnia; Jean‐François Morère



Printable version
Cyclooxygenase 2 inhibitors and lung carcinoma
Bulletin du Cancer. Volume 91, Number 1, 109-12, Janvier 2004, Synthèse
Résumé Article gratuit
Author(s) : Jean‐Philippe Spano, Kader Chouahnia, Jean‐François Morère
Summary : Cyclooxygenase‐2 (Cox2) may play a crucial role in lung carcinogenesis. In fact, overexpression of Cox2 is common in non‐small cell lung cancer (NSCLC) and seems to be associated with tumor progression, invasion and metastasis. In experimental animal models Cox2 has been shown to be involved in tumor angiogenesis, suggesting that Cox2 is a potential target for NSCLC therapy. Several in vivo studies have already shown that Cox2 specific inhibitors (celecoxib, rofecoxib) have anti‐tumor activity and clinical trials using Cox2 inhibitors are currently ongoing in patients with NSCLC.
Keywords : cyclooxygenase‐2 (Cox2), non‐small cell lung cancer (NSCLC), Cox2 inhibitors, angiogenesis